Piper Sandler raises argenx stock price target to $820 on Vyvgart success

Argenx (ARGX) received a price target increase to $820 from Piper Sandler, maintaining an Overweight rating, driven by robust Q2 2025 earnings that significantly surpassed forecasts and positive Phase 3 clinical trial results for its drug Vyvgart. The successful Vyvgart trial in seronegative generalized myasthenia gravis patients positions the company for a supplemental Biologics License Application by late 2025, expanding its addressable market and reinforcing strong analyst consensus for continued growth.

Analysis

Argenx presents a compelling growth case underpinned by strong clinical and financial execution. The positive Phase 3 ADAPT SERON trial for Vyvgart in seronegative generalized myasthenia gravis (gMG) patients is a significant de-risking event, positioning the company to file a supplemental Biologics License Application by the end of 2025. This development is set to expand Vyvgart's addressable market by approximately 11,000 patients in the U.S. alone. This clinical success is amplified by outstanding financial performance, evidenced by a Q2 2025 revenue of $1.74 billion and EPS of $6.32, which surpassed consensus estimates by 98.56% and 106.54% respectively, and contributed to an 88% revenue growth over the last twelve months. The uniform bullish sentiment from analysts, including Piper Sandler's price target increase to $820 and reiterated 'Overweight' or 'Outperform' ratings from JPMorgan, Oppenheimer, and RBC Capital, validates the company's trajectory. Near-term catalysts such as the prefilled syringe launch and global expansion are expected to sustain momentum, while the maturation of the non-Vyvgart portfolio provides long-term upside potential.

Key Decisions for Investors

• Given the confluence of positive trial data, a substantial earnings beat, and strong analyst consensus, investors should view these events as a significant validation of the company's growth strategy and market position.
• Monitor the progress toward the sBLA submission for Vyvgart by year-end 2025, as its successful filing and subsequent approval are key inflection points for unlocking the expanded seronegative gMG market.
• Investors should track the commercial execution of the ongoing prefilled syringe launch and global expansion efforts in upcoming financial reports, as these are cited as crucial near-term revenue drivers.
• For long-term valuation, pay close attention to updates on the non-Vyvgart pipeline, as its development is essential for diversifying future revenue streams and mitigating single-product concentration risk.